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Cytotoxic T  cells are generated in vivo during ailograft rejection and can be 
recovered from  mice bearing  an  allogeneic tumor.  From  this  circumstantial 
evidence, graft rejection is generally considered to be mediated by cytotoxic T 
lymphocytes. However, Loveland and his colleagues (1-3) challenged this notion 
by demonstrating that immunity to an allograft could be adoptively transferred 
to adult, thymectomized, irradiated, and bone marrow-reconstituted (ATXBM) 
mice by Lyt-2÷-depleted cells, but not by Lyt-l+-depleted cells. They interpreted 
this finding as indicating that Lyt-l+2-3  -  cells caused graft rejection, whereas 
Lyt-2  + cells did not. But, there is no direct evidence that Lyt-2  + cells of either 
the host or donor are not involved in graft rejection. Moreover, LeFrancois and 
Bevan (4) recently raised doubt about the validity of using ATXBM mice as a T 
cell-deficient model and of eliminating cells by ot-Lyt and complement to define 
T  cell subsets mediating certain immunological functions. They found that host- 
derived cytotoxic T  cells were activated long after adoptive transfer of Lyt-2  ÷- 
depleted cells and that donor-derived cytotoxic T  cells were activated soon after 
transfer of a  Lyt-1 ÷- or Lyt-2+-depleted population. Their results indicate that 
host-derived Lyt-2  + cells are present in ATXBM mice and that small numbers 
of viable  cells  remaining after  treatment with  antisera  and  complement can 
proliferate in vivo in response to continual antigenic stimulation. In fact, ATXBM 
mice do not seem to be truly T  cell-deficient (5).  There are many technical 
problems in  quantifying complex Lyt reagents, and these must be considered 
when evaluating findings obtained  by  their  use,  under conditions leading to 
incomplete elimination of a particular Lyt population (6, 7).  It is still  unknown 
whether host or donor Lyt-2  + cells are involved or have any functional role in 
rejection. 
In this study, to circumvent these problems, we directly evaluated the effect 
of Lyt monoclonal antibodies (mAb)  I  on syngeneic and semisyngeneic tumor 
rejection by administering them to recipient mice without exogenous comple- 
ment. The results indicate the apparent involvement of Lyt-2÷3  ÷ cells in tumor 
rejection. 
Abbreviations used in this paper:  mAb, monoclonal antibody; MEM, minimum essential medium. 
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Materials and Methods 
Mice.  C57BL/6 (B6),  BALB/c, and (BALB/c X B6)Fl (CB6Fj) mice were purchased 
from  Shizuoka  Laboratory Animal  Center  (Shizuoka, Japan).  B6-Lyt-l.1  and  B6-Lyt- 
2.1,3.1  mice were originally provided  by Dr.  E.  A.  Boyse,  Memorial  Sloan-Kettering 
Cancer Center,  New  York and  bred  in  our laboratory. (BALB/c  x  B6-Lyt-2.1,3.1)Fl 
(CB6-Lyt-2.1,3.1 FI) mice were obtained from our breeding colonies. The Lyt phenotypes 
of B6, B6 Lyt congeneic, and BALB/c mice are as follows: B6, Lyt-l.2,2.2,3.2;  B6-Lyt- 
1.1,  Lyt-1.1,2.2,3.2; B6-Lyt-2.1,3.1, Lyt-l.2,2.1,3.1; BALB/c, Lyt-l.2,2.2,3.2. 
Tumors.  B6RV2  is  a  B6  leukemia  induced  by injection  of neonatal  B6  mice with 
radiation leukemia virus (8).  RLdl  is a radiation-induced leukemia of BALB/c origin (9, 
10). These tumors were maintained in ascites form in the strain of origin. 
Antibodies.  The Lyt and Thy-1  mAb used in this study are listed in Table I. The Ig 
class of concentrated culture supernatants was determined by immunodiffusion. These 
were used in  the  form of ascites from hybridoma-bearing nu/nu  (BALB/c) mice. The 
concentration of antibodies in pooled ascites was determined by single radial immunodif- 
fusion  (11)  using  goat  anti-mouse  heavy  chain  antibodies  (Meloy  Laboratories,  Inc., 
Springfield, VA). 
Tumor Assay.  Tumors were harvested in Eagles' minimum essential medium (MEM) 
and washed twice with medium. Then the desired number of tumor cells (in 0.2 ml) was 
injected intradermally into the hacks of mice through a  30-gauge stainless steel needle. 
Before inoculation of tumor cells,  the hair was shaved with clippers. The diameters of 
tumors were measured with vernier calipers, twice, at right angles, to calculate the mean 
diameter. 
Intravenous Injection of Antibody.  Mice  were  anesthetized  with  ether  and  injected 
through the retrobulhar venous plexus with 0.2 ml of antibodies (ascites), diluted 1:4 with 
MEM, through a  1-ml disposable tuberculin syringe fitted with a 26-gauge needle (Ter- 
umo, Inc., Tokyo). 
Antibody-mediated,  Complement-dependent Cytotoxicity.  Tests  were  performed  as  de- 
scribed previously (12). Before tests on the Lyt phenotype of T  cells from the spleen or 
lymph node, dead cells were removed by density gradient centrifugation in bovine serum 
albumin (13). 
Results 
Effect  of In  Vivo  Administration  of Lyt  mAb  on  Tumor  Rejection  Mediated  by 
Syngeneic or Semisyngeneic Recipient Mice.  Fig.  1 illustrates the growth of B6RV2 
TABLE  I 
Description of Monodonal Lyt and Thy-1 Antibodies 
Antibody  Antibody 
Specificity  Immunization*  Ig class  titer*  concentration 
rag~rot 
Lyt-  1.1  B6 anti-DBA/2  #~  6,400-12,800  3.2 
Lyt-l.2  B6-Lyt-l.l anti-BALB/c  !  72a~  12,800-25,600  116.0 
Lyt-2.1  B6-H-2  a anti-B6-H-2k.CE-Lyt-2.1  :DS !  ~'2hK  6,400-12,800  3.0 
Lyt-2.2  (C3H/An × B6-Lyt-2.1)F, anti-ERLD  ~  ~,2ax  6,400-12,800  2.9 
Lyt-3.2  C58 anti-C58.CE-Lyt-3.2:DS  #x  204,800-409,600  2.5 
Thy-l.2  (A-Thy-l.1  × AKR-H-2b)FI  anti-ASLl  #x  409,600-819,200  0.7 
* For production of hybridoma, spleen cells from immunized mice were fused with BALB/c myeloma 
NS-I by the method of Krhler and Milstein (28). 
Reciprocal of antiserum  dilution giving 50% cell lysis in cytotoxic tests with thymocytes of the 
appropriate Lyt and Thy-1 phenotype. 
0 Provided by Drs. Shoji Kimura and Nobuhiko Tada. 
! Derived stock. 
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FIGURE 1.  Growth of B6RV2 leukemia in  B6  male (A) and female (B) mice injected 
intradermally  with 1 × 106 B6RV2. (1") Death from progressive  B6RV2 growth. The ratio of 
the number of mice in which  a tumor was recognized  macroscopically  to the number of mice 
injected with tumor cells is shown in A and B. Growth of B6RV2 in CB6F] mice is described 
elsewhere  (8). 
in B6 mice after intradermal injection of 1 x  106 B6RV2 cells. In male B6 mice 
(Fig.  1 A), tumors grew progressively until the mice generally died 2-4 wk after 
B6RV2 transplantation. In female B6 mice (Fig.  1B), initial B6RV2 growth was 
followed by tumor regression. These observations suggest that the H-Y antigen 
on B6RV2  was involved in B6RV2  rejection by female B6 mice, although the 
predominant antigen involved in humoral and cellular immunity of these mice 
against B6RV2 was a unique tumor antigen on B6RV2, and not the H-Y antigen, 
as  shown  previously  (8).  When  BALB.RL~I  leukemia cells  were  inoculated 
intradermally (5 x  105) into CB6FI  mice, tumor regression after initial growth 
was observed in  both  males and  females (9,  10).  In  BALB/c mice (male and 
female), RL~I grew progressively and generally killed the mice within 4-5 wk. 
Using these two tumor regression systems, B6RV2  rejection by B6 and B6- 
Lyt-2.1,3.1  female mice, and RL~I  rejection by CB6Ft  and CB6-Lyt-2.1,3.1FI 
mice, we investigated the effects of in vivo administration of Lyt and Thy-l.2 
mAb. mAb were injected intravenously into recipient mice on days 0, 4, and 8 
after tumor inoculation, and the growth of the tumors was observed. Figs. 2 and 
3 illustrate the results of Lyt-2 mAb on rejection of B6RV2 and RL~I, respec- 
tively. Figs. 4 and 5 show the results of Lyt-3 mAb on rejection of B6RV2 and 
RL~I,  respectively. Lyt-2.1  mAb blocked B6RV2  rejection by B6-Lyt-2.1,3.1 
female mice, and RL~I  rejection by CB6-Lyt-2.1,3.1FI  mice, but did not block 
B6RV2 rejection by B6 female mice or RL~I rejection by CB6F~  mice. On the 
other hand, Lyt-2.2 mAb blocked B6RV2 rejection by B6 female mice and RL~I 
rejection by both CB6-Lyt-2.1,3.1 F1 and CB6F~ mice, but did not block B6RV2 
rejection by B6-Lyt-2.1,3.1  mice. Lyt-3.2 mAb blocked B6RV2 rejection by B6 
female mice and  RL~I  rejection by  CB6FI  mice,  but  did  not  block  B6RV2 
rejection by B6-Lyt-2.1,3.1 female mice. In these experiments, mice were usually 
each injected three times. But we observed blocking of tumor rejection in mice 
given only a  single injection (50 #1) of Lyt-2,3  mAb on day 0.  Therefore, we 
investigated the effect of antibody injection at different stages during the course 
of tumor rejection. As shown in Fig. 6, a single injection of Lyt-2.2 mAb on day 
0, 3, 6, or 9 after inoculation of B6RV2 was effective for blocking rejection. No 
blocking effect was observed with Thy-1.2 mAb on B6RV2 rejection by B6 mice 348  Lyt-2,3  BLOCKING  OF  TUMOR  REJECTION 
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FIGURE 2.  Blocking of B6RV2 rejection  by in vivo administration of Lyt-2 mAb. B6-Lyt- 
2.1,3. l (A, B, C) and B6 (D, E, F) female  mice were either not treated (A, D) or were injected 
intravenously with Lyt-2.1 (B, E) or Lyt-2.2 (C, F) mAb on days 0, 4, and 8 after transplantation 
of 1 x  1  0 e B6RV2 cells. 
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FIGURE 3.  Blocking of BALB.RLdl rejection  by in vivo administration of Lyt-2 mAb. CB6- 
Lyt-2.1,3.1Fl  (A, B,  C) and  CB6F~  (D,  E, F) mice  were  either  not treated  (A,  D) or were 
injected  intravenously  with  Lyt-2.1  (B, E) or Lyt-2.2 (C,  F) mAb on days 0, 4, and  8 after 
transplantation of 5 x  10 5 RLdl cells. 
(Fig. 4) or on RLdl  rejection by CB6F]  mice (Fig.  5), or with Lyt-l.1  mAb on 
B6RV2 rejection by B6-Lyt-l.1  mice (data not shown). 
Direct Estimation  of the Lyt Phenotype of T Cells Derived from Mice Treated  with 
Lyt mAb.  Mice were injected intravenously  with Lyt or Thy-l.2 mAb on days 
0, 4, and 8. The serum antibody levels of individual mice were assayed kinetically 
after the last injection. Antibody activities gradually  fell and were generally not NAKAYAMA AND  UENAKA  349 
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FIGURE 4.  Effects of Lyt-3.2 and Thy-l.2 mAb on rejection of B6RV2. B6-Lyt-2.l,3.1  (A, 
B) and  B6 (C, D, E) mice were either not treated (A, C) or were injected intravenously with 
Lyt-3.2 (B, D) or Thy-1.2 (E) mAb on days 0, 4, and 8 after transplantation of 1 x  l0  s B6RV2 
cells. Lyt-3.2 mAb blocked rejection by B6, but not by B6-Lyt-2.1,3.1  mice. Thy-1.2 mAb did 
not block rejection by B6 mice. 
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FIGURE .5.  Effects of Lyt-3.2 and  Thy-l.2 mAb on  rejection of RLdl.  CB6FI  mice were 
either not treated (A) or were injected intravenously with Lyt-3.2 (B) or Thy-l.2 (C) mAb on 
days 0, 4, and 8 after transplantation  of 5  x  10 5 RLdl cells.  Lyt-3.2 mAb blocked rejection, 
whereas Thy-1.2 did not. 
detectable after 2-3  wk. After the antibody activity became undetectable, thy- 
mocytes, lymph node, and spleen cells were typed for Lyt and Thy-1 in direct, 
antibody-mediated, complement-dependent cytotoxicity tests.  Before  tests  on 
lymph  node  and  spleen  cells,  dead  cells  were  removed by  density  gradient 
centrifugation in  bovine serum albumin.  Normally, the thymocyte population 
was  ___90% positive for Thy-1,  Lyt-1,  Lyt-2, and  Lyt-3.  The  lymph node cell 
population contained ~40-45%  Thy-1 + and Lyt-1 + cells, and 30%  Lyt-2  + and 
Lyt-3  + cells. The spleen cells were approximately 35-40%  Thy-1 + and Lyt-1 + 
cells, and 25-30%  Lyt-2  + and Lyt-3  + cells. These results were not significantly 
different in the different strains of mice. Fig. 7 illustrates tests with lymph node 
cells from B6-Lyt-2.1, 3.1  and B6 mice injected with Lyt-2 mAb. -40-45%  of 
the lymph node cells from untreated mice or mice injected with Lyt-2 mAb to 350  Lyt-2,3  BLOCKING  OF  TUMOR  REJECTION 
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FIGURE 6.  Effect of Lyt-2  mAb  injected at  different  stages during  the course  of tumor 
regression. B6 mice were given a single injection of Lyt-2.2 mAb on day 0 (A),  3 (B),  6 (C), 
or 9 (D) after transplantation of 1 x  10  ° B6RV2 cells. (E) Untreated control. 
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FIGURE 7.  Direct Lyt phenotyping of T  cells from B6-LyL-2. i ,3.1  (A, B, C') and B6 (D, E, F) 
mice that were either not treated (A, D) or were injected intravenously with Lyt-2.1 (B, E) or 
Lyt-2.2 (C, F) mAb. Lymph node cells were typed for Thy-l.2 (O), Lyt-l.2 (O), Lyt-2.1 (A), 
Lyt-2.2 (&), and Lyt-3.2 (11), in antibody-mediated, complement-dependent cytotoxicity tests, 
after  elimination  of dead  cells  on  a  density  gradient  of bovine  serum  albumin.  (  ), 
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the alternative allele were Thy-1 + and Lyt-1 + cells, and 30%  were Lyt-2  + and 
Lyt-3  + cells. In contrast, lymph node cells from mice injected with Lyt-2 mAb to 
the appropriate allele contained ~40-45%  Thy-1  + and Lyt-1 + cells, and ~15% 
Lyt-2  + and  Lyt-3  + cells. These results indicate that  Lyt-2  + and -3  + cells were 
reduced to background level and that the T  cell population phenotype in these 
mice was  mainly Lyt-l+2-3  -.  Similar results were obtained  with spleen cells. 
Blocking of the Lyt-2÷3  + population was still observed on day 57 (8 wk), but had 
recovered partially on day 80 (11  wk), and completely on day 94 (14 wk), after 
the end of treatment with Lyt-2.1 or Lyt-2.2 mAb. Blocking was also observed 
in mice given only one or two injections of Lyt-2 and -3 mAb. In the thymocyte 
population, no blocking of the Lyt-2÷3  + population was observed. The cell yields 
and levels of T  cells (Thy-1 ÷ cells) in  the lymph node and spleen of B6 and 
CB6F~ mice after intravenous injection of Lyt-2.1, Lyt-2.2, or Lyt-3.2 mAb were 
not significantly different from those of untreated mice. Administration of Thy- 
1.2 mAb to B6 or CB6F~ mice, and of Lyt-l.1 mAb to B6-Lyt-l.1 mice, did not 
alter the Lyt population. 
Discussion 
There  are  several  differences between  the  characteristics of regression  of 
B6RV2  leukemia  mediated  by  B6  or  CB6FI  female  mice  and  those  of 
BALB.RL61 mediated by CB6F~ mice. First, as described in Results, H-Y antigen 
is apparently involved in the in vivo rejection of B6RV2, but not in that of RL~I. 
Second, an lr gene, possibly identical to the Rgv-I gene, is responsible for RL~I 
rejection. Thus,  RL~I  leukemia is rejected by hybrids of BALB/c and certain 
other mouse strains  that possess the responder allele, although BALB/c mice 
themselves exhibit no detectable resistance (9).  Third, the tumor sizes  during 
the course of regression of these two tumors are different. The peak diameter 
of B6RV2  reaches -20  mm, whereas that of RL~I  is no more than  10  mm. 
These differences suggest that the mechanisms of regression of these two tumors 
in syngeneic and semisyngeneic recipient mice are different. 
In the present study, we demonstrate that the rejection of these two tumors in 
syngeneic and semisyngeneic recipients was blocked by either Lyt-2 and -3 mAb 
administered in vivo without exogenous complement. The specificity of Lyt-2,3 
blocking was shown by the fact that the blocking activities of Lyt-2 and -3 mAb 
in recipient mice derived from B6 Lyt congeneic stocks were consistent with the 
Lyt phenotype of these mice, and that no blocking was observed after in vivo 
administration of Thy-1 or Lyt-1 (data not shown) mAb. These effects cannot 
be ascribed to a certain class of Ig because the Ig of Lyt-2.1, Lyt-2.2, and Lyt- 
3.2 mAb are ~2bx, "y2ax, and #K, respectively. Blocking of B6RV2 or BALB.RL~I 
rejection by Lyt-2.1 mAb in appropriate Lyt-congeneic recipient mice provided 
further proof that  Lyt-2 blocking was at  the effector level, not at  the target 
tumor cell level (Lyt phenotype of B6 and BALB/c, Lyt-l.2,2.2,3.2). 
There are several reports on  the effect of in  vivo administration of mAb. 
Infusion of Thy-l.1  mAb with or without exogenous complement has a  thera- 
peutic effect on AKR/J mice with transplanted AKRSL2  leukemia (14).  Since 
antigen-negative variants are not eliminated by the treatment, this effect appears 
to be at the target cell level. In the case of RBL-5 (B6) leukemia transplanted 352  Lyt-2,3  BLOCKING  OF  TUMOR  REJECTION 
into  BALB/c  mice,  injection of Thy-l.2  mAb tends to prolong the rejection 
time,  and  Lyt-1  or  Lyt-2  mAb  have  no  effect (15).  Michaelides  et  al.  (16), 
however, observed blocking of allograft rejection after administration of Lyt-1.1 
mAb to CBA/H mice. The reason for these discrepancies is unknown. Possible 
reasons are (a) differences in antigenic strength; ailogeneic and syngeneic (or 
semisyngeneic) tumor rejection used for assay of the effect, (b) different tumor 
types, or (c) differences in activity of mAb. 
It has been widely accepted that cytotoxic T  cells are effector cells in graft 
rejection. Recently, however, some investigators have raised questions about the 
functional role of Lyt-2  + cells as effectors in rejection of  allografts (1) or syngeneic 
tumors (17), by demonstrating that immunity is passively transferred to immu- 
nodeficient mice by spleen cells from which Lyt-2  + cells had been eliminated by 
treatment with a-Lyt-2 and complement. However, it was also shown that the 
adult thymectomized, irradiated, and bone marrow-reconstituted mice used in 
these studies were not truly T  cell deficient (5) and that,  in fact, host-derived 
cytotoxic T  cells immune to the allograft were recovered from mice to which 
Lyt-2÷-depleted populations  were adoptively transferred (4).  Thus,  it was still 
possible that  Lyt-2  ÷ cells are involved in  graft rejection. Recently (18),  it was 
reported that immunity to syngeneic fibrosarcoma can be adoptively transferred 
by  Lyt-2  +  cells.  Consistent  with  these  findings,  immunity  is  also  adoptively 
transferred by infusion of interleukin 2-dependent cytotoxic T cells to syngeneic 
tumors (19, 20) and allogeneic tumors (21) or tissue (22). Although our results 
support these findings and demonstrate directly that Lyt-2÷3  ÷ cells (and]or Lyt- 
2,3  antigen)  is  essential  for tumor  rejection by  syngeneic and  semisyngeneic 
recipients,  it  is  still  unknown by  which  mechanism Lyt-2  and  -3  mAb  cause 
blocking, or at which step of the rejection process Lyt-2 and -3 mAb are operative. 
The  finding that  a  single  injection  of Lyt-2  mAb  on  day  0-9  after  B6RV2 
transplantation effectively blocked tumor rejection suggests that effector cells 
were functionally blocked  rather than  that  the generation of these  cells was 
inhibited. Previously, we and others demonstrated that in vitro T cell cytotoxicity 
(6, 23-26) and proliferation (7, 27) in response to alloantigen stimulation, were 
blocked by 0t-Lyt-2,3  without added complement. We suggested that molecules 
bearing Lyt-2 and-3 determinants may be involved in T  cell recognition. The 
finding of Lyt-2,3 blocking of tumor rejection is consistent with these in vitro 
effects of ot-Lyt-2,3. 
The alteration of the T  cell population to result in Lyt-l+2-3  -  cell predomi- 
nance in the lymph node and spleen of mice injected with Lyt-2,3 mAb is also 
consistent with findings that,  in in vitro cultures of H-2 antigen-stimulated T 
cells, Lyt- 1  +2+3 + cells predominate under normal circumstances and Lyt- 1  +2-3- 
cells predominate when Lyt-l+2+3  + cells are blocked by Lyt-2 or -3 antiserum in 
the absence of complement (7). The decrease of Lyt-2÷3  + cells in mice injected 
with Lyt-2,3 mAb did not appear to be due to killing of Lyt-2+3  ÷ cells by Lyt 
mAb and complement from the recipient mice, because Thy-1 and Lyt-1 mAb 
(both  with  extremely high  titers  in  cytotoxic tests)  did  not  alter  the  T  cell 
population.  Our results do not  indicate why there was no change in  the  Lyt 
population  in  the thymus.  One possible  reason is  that  insufficient antibodies 
reached the thymus, because of the low blood supply or a barrier to the organ. NAKAYAMA AND  UENAKA  353 
Another reason could be that in the thymus, antibody-coated Lyt-2÷3  + cells were 
eliminated  rapidly  and  the  population  of uncoated  cells was continuously  re- 
newed. In contrast, in the lymph node and spleen, it is possible that the population 
of Lyt-2  + cells was not restored quickly after treatment  with antibody and that 
Lyt-1 +2-3- cells proliferated instead. 
Summary 
After transplantation  of B6RV2 leukemia, initial  tumor growth was followed 
by tumor regression in  B6 (CB6F~) female, but not male,  mice. This indicated 
that H-Y antigen  is involved in B6RV2 rejection by syngeneic female recipient 
mice.  In  the  case  of another  leukemia,  BALB.RIAI,  an  Ir  gene,  probably 
identical to the Rgv-I gene, is responsible for RIA1 rejection. Thus,  F1 hybrids 
of BALB/c with certain other strains of mice can reject RIA1. Using these two 
different  systems  of tumor  rejection,  we  investigated  the  effects  of in  vivo 
administration  of Lyt and Thy-1  monoclonal antibodies (mAb). Results showed 
that  Lyt-2 and -3 mAb blocked both B6RV2 rejection by B6 female mice and 
BALB.RLgl rejection by CB6F1 mice. The specificity of blocking was confirmed 
by use of Lyt-2 and -3 mAb to reciprocal alleles and mice from B6 Lyt-congeneic 
stocks. No blocking was observed with Lyt-1 and Thy-1 mAb. The Lyt phenotype 
of T  cells in  lymphoid  tissues from  mice treated  with  mAb was then  studied. 
Blocking of the Lyt-2+3  + population was observed in the lymph node and spleen, 
but not in the thymus. 
These results indicate the involvement of Lyt-2÷3  + cells (or Lyt-2,3 antigen) 
in tumor rejection. The precise mechanism  of blocking is unknown,  but it was 
observed after  even  a  single  injection  of Lyt-2,3  mAb on  day  9  after  tumor 
transplantation,  suggesting that effector cells were functionally blocked, rather 
than that the generation of these cells was inhibited. 
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